SEC Comment Letter 0000000000-24-009246 to IO Biotech, Inc. (IOBT)

IO Biotech, Inc.
Date: Aug. 13, 2024 · CIK: 0001865494 · Accession: 0000000000-24-009246

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-41008

Date

August 13, 2024

Author

Amy Sullivan

Form

UPLOAD

Company

IO Biotech, Inc.

Letter

August 13, 2024 Amy Sullivan Chief Financial Officer IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark Re:IO Biotech, Inc. Form 10-K for the fiscal year ended December 31, 2023 Filed March 5, 2024 File No. 001-41008 Dear Amy Sullivan: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

August 13, 2024
Amy Sullivan
Chief Financial Officer
IO Biotech, Inc.
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark
Re:IO Biotech, Inc.
Form 10-K for the fiscal year ended December 31, 2023
Filed March 5, 2024
File No. 001-41008
Dear Amy Sullivan:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io